Xuzhenda cooperates with Imena and Eurolink to create a one-stop multi-omics one-stop service platform

Today, China has become the world's second-largest pharmaceutical market, but there is still a long way to go before it becomes a real "pharmaceutical power"
.

China’s pharmaceutical industry has been innovating.
In the past 100 years, it has gone through the road from the sale of imported drugs, to the development of generic drugs and improved new drugs, to import substitution, and tracking innovation.
This has met the basic requirements of the world’s largest population.
Clinical needs
.

For example, through exploratory research on genomics, many new pathogenic factors have been discovered, which continues to promote the evolution of drugs
.

However, the occurrence and development of diseases is a complex process, and many factors such as gene mutations, epigenetic changes, gene expression levels, post-translational modifications, abnormal metabolic structures, etc.
, will affect the changes in the characteristics of life
.

At the 2021 Drug Information Association (DIA) China Annual Conference, a luncheon hosted by SEQUANTA in conjunction with Illumina and Olink will discuss how multi-omics technology can help drugs The discussion of research and development has become a hot spot
.

Create a one-stop platform for multi-omics testing technology

New drug research and development is a business full of challenges and uncertainties, with huge investment and few successful people
.

       Xu Zhenda has been creating such a high-quality multi-omics service platform covering genomes, transcriptomes, epitomomes, proteomics, etc.
, which connects first-class technologies and applications
.

       Among them, Inmana’s NGS service is the foundation of genomics and an indispensable core technology in multi-omics research
.

       "One of the great significance of the TCGA project is that by integrating and analyzing multi-omics data with genomics as the core, more accurate molecular typing of common cancers has been achieved
.

       Another "good partner" of Xu Zhenda, Oulinke, is good at multiple proteome detection technology
.
Its proteomic detection technology can also use NGS sequencer to generate data, which can be used in conjunction with the obtained genomic data to help scientists discover new drug targets and help scientists understand real-time biology more comprehensively and accurately
.
The cooperation between Xu Zhenda and Eurolink will jointly promote the promotion of advanced proteomics detection technology in China
.

       Mr.
Wei Lifeng, general manager of Eurolink China, pointed out that “the adoption of innovative technology has a process”, and he also said that from Eurolink’s experience, the development of multi-omics detection technology that combines multiple proteomes with genomes The speed is very impressive, "Eurolink entered the North American market from Sweden in 2016.
So far, at least 19 of the world's top 20 pharmaceutical companies are already customers of Allink
.
"

       He believes that China's local innovative companies are constantly seeking global competitiveness, and more and more drug research and development institutions have begun to upgrade their research and development, from tracking innovation to innovation at the source
.
In the process of competing with major international pharmaceutical companies, multi-omics testing technology will surely become an important research tool for some outstanding leading companies
.

       In the face of the aforementioned industrial changes, Xuzhenda has joined hands with technology providers such as Imena and Eurolink to create a multi-omics one-stop service platform based on high-standard laboratories with CLIA/CAP qualifications
.

       Clinical application of multi-omics technology

       In fact, the clinical application of multi-omics has already begun a few years ago, including indications such as tumors, autoimmune diseases, and infectious diseases
.
Professor Zhang Henghui of Capital Medical University believes that thanks to the diverse samples of body fluids and tissues, and the attention of the capital market, multi-omics exploration of tumors has made the fastest progress
.

       "In clinical aspects, especially the cognition of diseases, it has reached a higher dimension.
Data integration will provide us with more information
.
" Professor Yanan Cao, a researcher at Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine, compares.
"Whether it is diagnosis, treatment or related drug research and development, the low-hanging fruits have been picked
.
How we find new targets and diagnostic methods must return to technological progress
.
"

       In other words, current basic research requires larger sample sizes and more complex experimental designs; from a data perspective, it also requires higher resolution
.
The connotation of resolution is that we have to switch from the past group perspective to the individual perspective, genomics perspective, proteomics perspective, and then to the application of multiomics perspective today
.

Professor Yanan Cao added: “I think everyone can reach a consensus.
Through these breakthroughs in data and production technology, it may bring more opportunities to the field of biomedicine
.
In the final clinical application, domestic research, including the resulting The data can provide more targeted help to local patients
.
"

       This is not only Professor Cao Yanan's wish, but also Xu Zhenda's vision
.
Dr.
Li Yuan, the head of Xuzhenda R&D Center, believes that a professional and high-quality service platform can better enable the upstream and downstream partners of multiple omics to mutually empower each other
.
And this is also an important proposition to help create a good ecology for precision medicine, especially the research and development of innovative drugs
.

       How to build a multi-omics industrial ecology?

       "A good ecological environment involves many aspects, including national policies, as well as investors, which will have a great impact and promotion on the industry
.
" Dr.
Wang Min said, "If you can summarize it in one word, I think it is'shun '
.
Standing at the forefront and vent of multi-omics studies, solidly do a good job of basic scientific research, and actively explore application areas, so that we can better grasp the development direction and opportunities of the industry
.
"

       Not only enterprises, but also research institutions, clinical institutions, and investment institutions need to be involved
.
As Mr.
Wei Lifeng said, different ecology in nature develops around the sun.
Whether it is drug development or early tumor screening and other application scenarios, it is important to find a diver like the sun in nature
.

       "For us, unmet clinical needs are a continuous driving force
.
We are willing to serve the entire precision medicine market around this original intention
.
" Mr.
Wei Lifeng further added
.

       Professor Zhang Henghui shared his views from the perspective of clinical resources, funding, and talent team support
.
"Stable laboratory services, bioinformatics analysts, and continuous funding support are needed to make the entire ecology develop in a sustainable direction
.
"

       At the event site, Xu Zhenda and Eurolink reached a strategic cooperation contract
.
The two parties will jointly utilize their respective superior resources to continue to promote the implementation and application of multi-omics technologies
.

       "In the entire multi-omics research, we really need more innovation and more cooperation.
What Xu Zhenda can do in this regard is that we bring advanced technology at home and abroad to our partners and become a high-quality Multi-omics platform, and then interact with everyone, collisions and sparks, find better opportunities to serve clinical research in the multi-omics field
.
” Dr.
Li Yuan looked forward to finally saying
.